Analyst Price Targets — TNDM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 23, 2026 11:41 am | — | Deutsche Bank | $15.50 | $14.34 | TheFly | Tandem Diabetes initiated with a Hold at Deutsche Bank |
| June 1, 2026 1:11 am | — | Wells Fargo | $27.00 | $17.20 | TheFly | Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo |
| May 27, 2026 11:27 am | — | Goldman Sachs | $21.00 | $14.54 | TheFly | Tandem Diabetes price target lowered to $21 from $24 at Goldman Sachs |
| May 11, 2026 9:49 am | — | Barclays | $55.00 | $15.48 | TheFly | Tandem Diabetes price target lowered to $55 from $56 at Barclays |
| May 8, 2026 11:20 am | Anthony Petrone | Mizuho Securities | $24.00 | $18.47 | TheFly | Tandem Diabetes price target raised to $24 from $22 at Mizuho |
| April 24, 2026 8:58 am | Issie Kirby | Redburn Partners | $45.00 | $20.68 | TheFly | Tandem Diabetes price target raised to $45 from $36 at Rothschild & Co Redburn |
| February 23, 2026 12:44 pm | — | Truist Financial | $27.00 | $24.57 | TheFly | Tandem Diabetes price target raised to $27 from $24 at Truist |
| February 23, 2026 12:44 pm | — | Lake Street | $50.00 | $24.57 | TheFly | Tandem Diabetes upgraded to Buy from Hold at Lake Street |
| February 23, 2026 11:46 am | David Roman | Goldman Sachs | $28.00 | $24.57 | TheFly | Tandem Diabetes price target raised to $28 from $25 at Goldman Sachs |
| February 23, 2026 10:52 am | Matt Miksic | Barclays | $56.00 | $24.57 | TheFly | Tandem Diabetes price target raised to $56 from $55 at Barclays |
Latest News for TNDM
Tandem Diabetes Care, Inc. TNDM is well-poised to grow in the coming quarters as the rising prevalence of diabetes and increasing adoption of connected care continue to support demand for automated insulin delivery. The company's pay-as-you-go reimbursement model could lower upfront barriers for pump starts and support higher supply revenue per customer over time.
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five EU countries.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after th
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial…
Tandem Diabetes Care, Inc. (TNDM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TNDM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.